©2024 Stanford Medicine
Palatability and Tolerability of Deferasirox Taken With Meals, With Different Liquids or Crushed and Added to Food
Not Recruiting
Trial ID: NCT00845871
Purpose
This single-arm, open-label, multi-center study enrolled 65 patients from approximately 20
centers. All patients who met the study criteria and were taking, beginning or resuming
treatment with Deferasirox were allowed. The study will began with a one month run-in phase,
where all patients were instructed to take Deferasirox according to their physician's
prescribing information.
Official Title
A Single-arm, Open-label Study of the Palatability and Tolerability of Deferasirox Taken With Meals, With Different Liquids or Crushed and Added to Food
Eligibility
Inclusion Criteria:
- Male or female patients with thalassemia major, sickle cell disease (SCD), low or
intermediate 1 (INT 1) risk myelodysplastic syndrome (MDS) or other anemias and
transfusional hemosiderosis.
- Patients who were on, starting, or resuming treatment with Exjade.
- Patients who were >2 years (i.e., 2 years of age or older).
Exclusion criteria:
- Serum creatinine above the upper limit of normal (ULN) for age.
- Alanine aminotransferase (ALT) >2.5 times the ULN.-High risk intermediate-2 or high
risk MDS or acute leukemia.
Intervention(s):
drug: deferasirox:
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Peds Hem/Onc CRAs
650-723-5535